Amgen initiated with an Equal Weight at Barclays

Barclays initiated coverage of Amgen (AMGN) with an Equal Weight rating and $185 price target Given that there is “plenty of time” until the Phase 3 MARITIME readout, the “biggest source of debate” on Amgen would have concrete answers for some time, the analyst tells investors. The firm adds that it is “probably a bit more negatively inclined on this than the Street,” but says this is offset by Amgen’s “strong” guidance.